A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver

Exclusion Criteria

• •Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
• •Resting heart rate \> 100 beats per minute (bpm) and/or systolic blood pressure ≥ 160 millimetre of mercury (mmHg) and/or diastolic blood pressure ≥95 mmHg at screening.
• •* Low-density lipoprotein (LDL) \> 160 mg/dL (4.15 mmol/L)
• •* total cholesterol \>240 mg/dL (6.22 mmol/L)
• •* triglyceride \>200 mg/dL (2.26 mmol/L)
• •* blood glucose \> 126 mg/dl (\>7 mmol/L) fasting and/or glycated haemoglobin (HbA1c) \>6.5% (\>48 mmol/mol)
• •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders assessed as clinically relevant by the investigator
• •Diseases of the central nervous system (including but not limited to any kind of seizures), and other relevant neurological or psychiatric disorders
• •History of relevant orthostatic hypotension, fainting spells, or blackouts
• •Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, manifest hypo- or hyperthyroidism at Visit 1
• •Further criteria apply